LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the ankylosing spondylitis market. The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat ankylosing spondylitis.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Ankylosing Spondylitis - market overview
Ankylosing Spondylitis is derived from two words - ankylosing meaning fusion and spondylitis meaning inflammation of the spine. It causes severe chronic pain and discomfort to the patient. Ankylosing Spondylitis gradually spreads to other areas of the body such as shoulders, hips, heels, and small joints of the hand and feet.
According to a senior analyst at Technavio for central nervous system research, “In advanced cases, disease progression can lead to overgrowth of bones, which results in abnormal joining of bones or fused vertebrae, thus affecting the mobility of the patient.”
Companies primarily comprising of private players dominated the drug development space for ankylosing spondylitis. Public institutions involved in healthcare and education sectors such as University College, Dublin and Tabriz University of Medical Sciences are also involved in drug development.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Ankylosing spondylitis segmentation
This market research report segments the ankylosing spondylitis market based on RoA (oral, intravenous, and subcutaneous), therapeutic modalities (small molecules and biological molecule), targets for drugs under development (Janus kinase -1, TNF alpha, and interleukin) and mechanism of action (JAK -1 inhibitor, interleukin inhibitor and TNF inhibitor).
The subcutaneous RoA is expected to account for around 73% of the market share followed by the oral and intravenous segments. In terms of therapeutic modalities, the biological molecule segment accounted for 82% of the market share. Biological molecules or natural atoms is a term used for particles that are available in all live forms. Biomolecules include macro-molecules or polyanions such as protein, starches, lipids and nucleic acids.
|
Save big with Technavio this May! Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all
non-alcoholic
beverages reports for the entire month.
OR Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
